** Sino Biopharmaceutical 1177.HK rises 4.3% to HK$3.41; set for biggest one-day pct gain since Oct. 18
** Co buys 4.91% stake in LaNova Medicines for 142 mln yuan ($19.6 mln), enters into agreement for LM-108, a monoclonal antibody for various solid tumour treatment currently at Phase II clinical stage, in Mainland China region
** Says further cooperations with LaNova for various innovative bispecific antibody and antibody-drug conjugates in its pipelines
** Hong Kong's healthcare index .HSCIH up 2.9%
** Stock down 5.8% YTD
($1 = 7.2418 Chinese yuan renminbi)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。